Brain Cancer Clinical Trials

Brain: Treatment Trials

Study Title: A071401: Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations
Primary/Site/Co-Investigator: Alissa Thomas, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Brain: Symptom Management & Quality of Life

Study Title: UVMCC 1702: Venous thromboembolism (VTE) prevention in patients with malignant glioma
Primary/Site/Co-Investigator: Alissa Thomas, MD
For more Information: call the UVM Cancer Center Clinical Trials Office at (802)656-4414 ext. 2
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: MSKCC 15-034 GBM Coping: Coping with glioblastoma: A study of communication between physicians, patients, and caregivers
Primary/Site/Co-Investigator: Alissa Thomas, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: UVMCC 1603: Fatigue in Patients with Primary Brain Tumors
Primary/Site/Co-Investigator: Alissa Thomas, MD
For more Information: call the UVM Cancer Center Clinical Trials Office at (802)656-4414 ext. 2
To Learn More or Enroll: Call (802)656-4414 ext. 2

Breast Cancer Clinical Trials

Breast: Treatment Trials 

Study Title: NSABP B-51 - A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Primary/Site/Co-Investigator: Michelle Sowden, DO
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: NRG-BR003: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Primary/Site/Co-Investigator: Marie Wood, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: A011202: A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Primary/Site/Co Investigator: Michelle Sowden, DO
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: A011502: A Randomized Phase III Double Blind Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
Primary/Site/Co-Investigator: Marie Wood, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: AFT25 COMET: Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial
Primary/Site/Co-Investigator: Jessica Cintolo-Gonzalez, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: A221505: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction
Primary/Site/Co-Investigator: Carl Nelson, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: A171601: A Phase II Trial Assessing the Tolerability of Palbociclib in Combination with Letrozole or Fulvestrant in Patients Aged 70 and Older with Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer
Primary/Site/Co-Investigator: Peter Kaufmann, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

 Breast: Symptom Management & Quality of Life Trials

Study Title: A221405 POSITIVE: A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women With Endocrine Responsive Breast Cancer Who Desire Pregnancy (POSITIVE)
Primary/Site/Co-Investigator: Kim Dittus, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: A211601: Evaluation of Mammographic Breast Density Effect of Aspirin: A Companion Study to Alliance Study A011502
Primary/Site/Co-Investigator: Marie Wood, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Bladder Cancer Clinical Trials

Bladder: Treatment Trials 

Study Title: D933RC00001- NIAGARA-A Phase III Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine & Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer (NIAGARA)
Primary/Site/Co-Investigator: Steven Ades, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: A031501: Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) versus Observation
Primary/Site/Co-Investigator: Steven Ades, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: MK3475-676: A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475 in Combination with Bacillus Calmette-Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cander (HR NMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)
Primary/Site/Co-Investigator: Scott Perrapato, DO
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

 Colon Cancer Clinical Trials

Colon: Treatment Trials

Study Title: S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
Primary/Site/Co-Investigator: Krista Evans, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Esophageal Cancer Clinical Trials

Esophageal: Symptom Management & Quality of Life

Study Title: UVMCC 1606: Quality of Life Assessment for Head and Neck Cancer Patients Undergoing Treatment in the First Year of Survivorship
Primary/Site/Co-Investigator: Maura Barry, MD
For more Information: call the UVM Cancer Center Clinical Trials Office at (802)656-4414 ext. 2
To Learn More or Enroll: Call (802)656-4414 ext. 2

Head and Neck Cancer Clinical Trials

Nead and Neck: Treatment Trials

Study Title: MK-3475-689-A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)
Primary/Site/Co-Investigator: Mirabelle Sajisevi, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Kidney Cancer Clinical Trials

Kidney: Treatment Trials

Study Title: EA8143: A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Primary/Site/Co-Investigator: Scott Perrapato, DO, FACOS
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Lung Cancer Clinical Trials

Lung: Treatment Trials

Study Title: S1800A-A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
Primary/Site/Co-Investigator: Hibba Rehman, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: LUNGMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (LUNG-MAP Screening Study)
Primary/Site/Co-Investigator: Hibba Rehman, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: S1900A- A Phase II Study of Rucaparib in Patients with Genomic LOH- or BRCA-Positive Stage IV or Recurrent NSCLC (LUNG-MAP Sub-Study)
Primary/Site/Co-Investigator: Hibba Rehman, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: A081105: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) 
Primary/Site/Co-Investigator: Hibba Rehman, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: ECOG-ACRIN E4512: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Primary/Site/Co Investigator: Hibba Rehman, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: ECOG EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Primary/Site/Co Investigator: Hibba Rehman, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: CA209-816: Randomized, Open-Label, Phase 3 Trial of Nivolumab and Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC
Primary/Site/Co Investigator: Farrah Khan, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: UVMCC 1800: Pilot Study involving Active Surveillance with CT Imaging and Liquid Biopsies For Inoperable Stage IA Lung Cancer in the Elderly
Primary/Site/Co Investigator: Christopher Anker, MD
For more Information: call the UVM Cancer Center Clinical Trials Office at (802)656-4414 ext. 2
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: EA5163 - A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer with Immunobiomarker SIGNature-driven Analysis
Primary/Site/Co Investigator: Janet Kahn, PhD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Lung: Symptom Management & Quality of Life

Study Title: A211401: Reducing Surgical Complications in Newly Diagnosed Lung Cancer Patients Who Smoke Cigarettes
Primary/Site/Co Investigator: Garth Garrison, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
 

Lymphoma Clinical Trials

Lymphoma: Treatment Trials 

Study Title: Genentech ML29496: Maintenance Obinutuzumab for primary Central Nervous System Lymphoma Complete Responders
Primary/Site/Co Investigator: Alissa Thomas, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
 
Study Title: EA4151: A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
Primary/Site/Co Investigator: Julian Sprague, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
 

Melanoma Clinical Trials

Melanoma: Treatment Trials 

Study Title: ECOG EA6141: Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Primary/Site/Co-Investigator: Christopher Anker, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Multiple Cancer Sites Clinical Trials

Multiple Cancer Sites: Treatment Trials 

Study Title: EAY131 (MATCH): Molecular Analysis for Therapy Choice (MATCH), Master Protocol 
Primary/Site/Co-Investigator: Marc Greenblatt, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors
Primary/Site/Co Investigator: Hibba Rehman, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: AFT28 CANVAS: Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin for VTE in Cancer: A randomized Effectiveness Trial (CANVAS trial)
Primary/Site/Co Investigator: Chris Holmes, MD, PhD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: MS201781-0031: A Phase Ib Open Label, Dose Finding Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination with M9241 (NHS-IL12) in Subjects with Locally Advanced, Unresectable, or Metastatic Solid Tumors
Primary/Site/Co-Investigator: Steven Ades, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Multiple Cancer Sites: Symptom Management & Quality of Life

Study Title: EPIPHANY 10001-Chemotherapy Induced Peripheral Neuropathy Natural History Study (EPIPHANY)
Primary/Site/Co-Investigator:Noah Kolb, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: UVMCC 1518 (VTE-PACC): VTE Prophylaxis in the Ambulatory Cancer Clinic (VTE-PACC)
Primary/Site/Co-Investigator: Chris Holmes, MD, PhD
For more Information: call the UVM Cancer Center Clinical Trials Office at (802)656-4414 ext. 2
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: A221602: Olanzapine with or without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patients receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double-Blind, Placebo-Controlled Trial
Primary/Site/Co-Investigator: Steven Ades, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Ovarian Cancer Clinical Trials

Ovarian: Treatment Trials 

Study Title: VBL-111-701, GOG 3018 OVAL - The OVAL Study: A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Primary/Site/Co-Investigator: Evelyn Cantillo, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: NRG GY005: A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS)
Primary/Site/Co-Investigator: Cheung Wong, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: CO-338-097 ARIES, A Phase 2, Open-Label Study to Evaluate Rcuaparib in Combination with Nivolumab in Patients with Selected Solid Tumors (ARIES)
Primary/Site/Co-Investigator: Evelyn Cantillo, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Prostate Cancer Clinical Trials

Prostate: Treatment Trials

 
Study Title: NRG GU006: A phase II, double-blinded placebo controlled randomized trial of salvage radiotherapy with or without enhanced anti-androgen therapy with apalutamide in recurrent prostate cancer
Primary/Site/Co-Investigator: James Wallace, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: NRG GU005: Phase III Image-Guided RadiationTherapy (IGRT) and Stereotactic Body Radiation Therapy (SBRT) vs. IGRT and Hypofractionated Intensity-Modulated Radiation Therapy (IMRT) for localized intermediate risk prostate cancer
Primary/Site/Co-Investigator: Nataniel Lester-Coll, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: I3Y-MC-JPCM: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer
Primary/Site/Co-Investigator: Steven Ades, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Rectum Cancer Clinical Trials

Rectum: Treatment Trials

Study Title: S0820:A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
Primary/Site/Co-Investigator: Krista Evans, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: MSKCC 13213: A phase II multicenter randomized trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or non-operative manage
Primary/Site/Co-Investigator: Peter Cataldo, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: NRG GI002: A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
Primary/Site/Co-Investigator: Christopher Anker, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: EA2165: A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Primary/Site/Co-Investigator: Maura Barry, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Other Ways to Help Advance Cancer Research

Study Title: UVMCC 1902 PROMISE, Prostate Cancer Circulating miRNAs for Precision-based Medicine (PROMISE)
Primary/Site/Co-Investigator: Steven Ades, MD
For more Information About this Trial: call the UVM Cancer Center Clinical Trials Office at (802)656-4414 ext. 2
To Learn More or Enroll: Call (802)656-4414 ext. 2
Breast Study Title: UVMCC 1515: Assessment of intrinsic fluorescence as a diagnostic tool for breast cancer tumors and nodal involvement
Primary/Site/Co Investigator: Gary Stein, PhD
For more Information: call the UVM Cancer Center Clinical Trials Office at (802)656-4414 ext. 2
To Learn More or Enroll: Call (802)656-4414 ext. 2
Breast Study Title: VCC 1106: Tumor Binding Antibodies from Cancer Patients
Primary/Site/Co Investigator: David Krag, MD
For more Information: call the UVM Cancer Center Clinical Trials Office at (802)656-4414 ext. 2
To Learn More or Enroll: Call (802)656-4414 ext. 2
Breast & Ovarian Study Title: V0308:  Clinical and Molecular Markers of Risk for Breast and Ovarian Cancers
Primary/Site/Co Investigator: Marie Wood, MD
For more Information: call the UVM Cancer Center Clinical Trials Office at (802)656-4414 ext. 2
To Learn More or Enroll: Call (802)656-4414 ext. 2
Breast Study Title: UVMCC 1704: The DNA Repair Landscape of Women at Risk for Breast Cancer: Family Studies Companion
Primary/Site/Co Investigator: Marie Wood, MD
For more Information: call the UVM Cancer Center Clinical Trials Office at (802)656-4414 ext. 2
To Learn More or Enroll: Call (802)656-4414 ext. 2
Breast Study Title: VCC 1205: The DNA Repair Landscape of Women at Risk for Breast Cancer
Primary/Site/Co Investigator: Marie Wood, MD
For more Information: call the UVM Cancer Center Clinical Trials Office at (802)656-4414 ext. 2
To Learn More or Enroll: Call (802)656-4414 ext. 2
Lung Study Title: A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Primary/Site/Co Investigator: Hibba Rehman, MD
For more Information: call the UVM Cancer Center Clinical Trials Office at (802)656-4414 ext. 2 or Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Colon Cancer Study Title: UVMCC 1901, Use of digital PET scanning to identify lymphatic metastases in colon cancer
Primary/Site/Co Investigator: Peter Cataldo, MD
For more Information: call the UVM Cancer Center Clinical Trials Office at (802)656-4414 ext. 2
To Learn More or Enroll: Call (802)656-4414 ext. 2
Multiple Sites Study Title:  VCC 1107: Oncology Rehabilitation Database
Primary/Site/Co Investigator: Kim Dittus, MD
For more Information: call the UVM Cancer Center Clinical Trials Office at (802)656-4414 ext. 2
To Learn More or Enroll: Call (802)656-4414 ext. 2

About Us

FAQs

Contact Us

 

Trials by Cancer Type

Click below to view open cancer trials by type. 

Brain Breast Bladder ColonEsophagealHead and Neck KidneyLungLymphomaMelanomaMultiple SitesOvarianPediatric ProstateRectumOther Ways to Help Advance Cancer Research

Enroll Now

If you have any questions or would like to enroll in one of these clinical trials, please call (802) 656-4414 ext. 2.